BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


SEARCH JOBS

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at www.oncogenex.com

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678



 Key Statistics


Email:
Ownership: Private

Web Site: OncoGenex Pharmaceuticals Inc.
Employees:
Symbol: 
 









 Company News
OncoGenex Pharmaceuticals Inc. Reports Financial Results For Fourth Quarter And Year End 2013 3/12/2014 6:43:24 AM    More...
OncoGenex Pharmaceuticals Inc. To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014 2/25/2014 6:18:37 AM    More...
OncoGenex Pharmaceuticals Inc. Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer 2/11/2014 10:05:46 AM    More...
OncoGenex Pharmaceuticals Inc. To Present At Leerink Swann and Company Global Healthcare Investor Conference 2/6/2014 6:22:28 AM    More...
OncoGenex Pharmaceuticals Inc. Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer 11/19/2013 11:26:30 AM    More...
OncoGenex Pharmaceuticals Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call 11/8/2013 6:53:41 AM    More...
OncoGenex Pharmaceuticals Inc. to Present at Credit Suisse Healthcare Investor Conference 11/5/2013 6:50:31 AM    More...
OncoGenex Pharmaceuticals Inc. to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013 10/30/2013 6:53:16 AM    More...
OncoGenex Pharmaceuticals Inc. Announces that the Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) in Combination With ABRAXANE® Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer is Now Open for Enrollment 8/29/2013 9:04:40 AM    More...
OncoGenex Pharmaceuticals Inc. Announces that the Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) in Combination With ABRAXANE® Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer is Now Open for Enrollment 8/27/2013 7:35:33 AM    More...
12345678910...

//-->